Protalix BioTherapeutics, Inc. PLX
Set alert
2.59 USD -0.02 -0.77%
At close · Oct 30
2.56 -0.03 -1.16%
After hours · Oct 30, 5:05 PM ET
2.57 Day range 2.62
1.67 52-week range 3.15
- YTD
- +43.89%
- 1 year
- +14.60%
- Open
- 2.60
- Prev close
- 2.61
- Mkt cap
- 208.68M
- Vol
- 249.29K
- Avg vol
- 800.78K
- EPS
- 0.23
- P/E
- 11.26
- Div yield
- 0.00%
More statistics
- Low
- 2.57
- High
- 2.62
- Forward P/E
- 2.79
- Beta
- 0.67
- Short ratio
- 22.71
- Inst. own
- 5.20%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.43
- 200-d avg
- 1.21
- 1y target
- 14.00
2Y chart
Events in this range
- Nov 14, 2024Earnings: 0.03; estimate 0.06; surprise -50%
Signals (75)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 19, 2026 | 1 week ago |
| MACD: Sell Signal | Sep 25, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 26, 2026 | 2 months ago |
| SMA: Bearish | Aug 14, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 14, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
| SMA: Bullish | Jun 24, 2026 | 4 months ago |
| SMA: Bearish | Jun 22, 2026 | 4 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
| MACD: Buy Signal | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 5, 2026 | 5 months ago |
| MACD: Sell Signal | May 5, 2026 | 5 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 28, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 8, 2026 | 6 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| MACD: Sell Signal | Feb 25, 2026 | 8 months ago |
| RSI: Overbought | Feb 11, 2026 | 8 months ago |
| RSI: Overbought | Jan 30, 2026 | 9 months ago |
| SMA: Bullish | Jan 8, 2026 | 9 months ago |
| SMA: Bullish | Jan 8, 2026 | 9 months ago |
| MACD: Buy Signal | Dec 8, 2025 | 10 months ago |
| SMA: Bearish | Nov 13, 2025 | 11 months ago |
| SMA: Bearish | Nov 10, 2025 | 11 months ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| SMA: Bearish | Oct 17, 2025 | 1 year ago |
| SMA: Bearish | Oct 17, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 14, 2025 | 1 year ago |
| RSI: Overbought | Sep 29, 2025 | 1 year ago |
| SMA: Bullish | Sep 24, 2025 | 1 year ago |
| SMA: Bearish | Sep 23, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| RSI: Overbought | Sep 22, 2025 | 1 year ago |
| RSI: Overbought | Sep 15, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 9, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 5, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 2, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 29, 2025 | 1 year ago |
| SMA: Bullish | Aug 18, 2025 | 1 year ago |
| SMA: Bearish | Aug 15, 2025 | 1 year ago |
| SMA: Bullish | Aug 7, 2025 | 1 year ago |
| SMA: Bearish | Jul 25, 2025 | 1 year ago |
| SMA: Bullish | Jul 22, 2025 | 1 year ago |
| RSI: Oversold | Jun 23, 2025 | 1 year ago |
| RSI: Oversold | Jun 17, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 3, 2025 | 1 year ago |
| RSI: Oversold | May 27, 2025 | 1 year ago |
| SMA: Bearish | May 9, 2025 | 1 year ago |
| RSI: Oversold | May 9, 2025 | 1 year ago |
| MACD: Sell Signal | May 6, 2025 | 1 year ago |
| RSI: Overbought | Apr 30, 2025 | 1 year ago |
| RSI: Overbought | Apr 23, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 15, 2025 | 1 year ago |
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 7, 2025 | 1 year ago |
| SMA: Bearish | Apr 4, 2025 | 1 year ago |
| SMA: Bullish | Mar 21, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 21, 2025 | 1 year ago |
| SMA: Bearish | Mar 18, 2025 | 1 year ago |
| SMA: Bullish | Mar 17, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 11, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 5, 2025 | 1 year ago |
| RSI: Overbought | Feb 5, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 27, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 21, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 17, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 3, 2025 | 1 year ago |
| RSI: Overbought | Jan 2, 2025 | 1 year ago |
| RSI: Overbought | Dec 30, 2024 | 1 year ago |
| RSI: Overbought | Dec 9, 2024 | 1 year ago |
Key statistics
- Market cap
- 127.39M
- Enterprise value
- 84.82M
- Trailing P/E
- 0.00
- Forward P/E
- 2.79
- PEG ratio
- 0.00
- Price / sales
- 3.35
- Price / book
- 3.76
- EPS (TTM)
- -0.15
- Beta
- 0.67
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -38.62%
- Revenue (TTM)
- 38.05M
- Revenue growth
- -61.60%
- Free cash flow
- 1.32M
- Total cash
- 45.03M
- Total debt
- 26.15M
- Return on equity
- -43.48%
- Shares outstanding
- 73.63M
- Short % of float
- 4.41%
- 50-day average
- 1.43
- 200-day average
- 1.21
Analyst view
Consensus: none
Price target (mean) 14.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
PLX Revenue — quarterly 19.90M
PLX Net income — quarterly 3.78M
PLX EPS — quarterly 0.05
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.06 | 0.03 | -0.03 | -50.00% |
| Aug 14, 2024 | Jun 1, 2024 | 0.02 | -0.03 | -0.05 | -250.00% |
| May 10, 2024 | Mar 1, 2024 | 0.00 | -0.06 | — | — |
| Mar 14, 2024 | Dec 1, 2023 | -0.03 | -0.07 | -0.04 | -133.33% |
| Nov 6, 2023 | Sep 1, 2023 | -0.07 | -0.04 | +0.03 | +42.86% |
| Aug 7, 2023 | Jun 1, 2023 | -0.04 | 0.21 | +0.25 | +625.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2023 | HC Wainwright & Co. | main | Buy | Buy |
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- protalix.com
News
- Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target
- Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
- Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript
- Protalix BioTherapeutics Q2 EPS $0.05 Misses $0.12 Estimate, Sales $19.896M Beat $12.931M Estimate
- Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
- Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript
- Earnings Scheduled For May 13, 2026
Your note
Sign in to keep a note on PLX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASHAN DROR | Chief Executive Officer | Stock Award(Grant) | Mar 31, 2024 | 0 |
| HAYON YAEL | Officer | Stock Award(Grant) | Aug 14, 2023 | 0 |
| NAOS YARON | Officer | Stock Award(Grant) | Aug 14, 2023 | 0 |
| RUBIN EYAL | Chief Financial Officer | Stock Award(Grant) | Sep 22, 2024 | 0 |
| SCHWARTZ AHARON | Director | Purchase | Jan 2, 2023 | 174,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 1.30% | 955,900 | 1.65M | Sep 29, 2024 |
| Gsa Capital Partners Llp | 0.59% | 435,213 | 752.92K | Sep 29, 2024 |
| Millennium Management Llc | 0.51% | 373,757 | 646.60K | Sep 29, 2024 |
| Stratos Wealth Partners, Ltd. | 0.37% | 270,000 | 467.10K | Sep 29, 2024 |
| Bridgeway Capital Management, Inc. | 0.25% | 183,790 | 317.96K | Sep 29, 2024 |
| Blackrock Inc. | 0.24% | 178,784 | 309.30K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.24% | 180,000 | 311.40K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.22% | 162,696 | 281.46K | Oct 30, 2024 |
| EQ Advisors Trust-1290 VT Micro Cap Port | 0.02% | 14,966 | 25.89K | Sep 29, 2024 |
| Northern Small Cap Core Fund | 0.00% | 503 | 870 | Sep 29, 2024 |
| John Hancock Var Ins Tr-Total Stock Market Index Tr | 0.00% | 640 | 1.11K | Sep 29, 2024 |